Hanmi Pharm Geçmiş Kazanç Performansı

Hala bu şirketin son kazanç raporunu inceliyoruz

Geçmiş kriter kontrolleri 5/6

Hanmi Pharm yıllık ortalama 38.8% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 11.5% annual. Gelirler growing yılda ortalama 8.1% oranında artmaktadır. Hanmi Pharm'in özkaynak karlılığı 17% ve net marjı 11.8%'dir.

Anahtar bilgiler

38.8%

Kazanç büyüme oranı

39.0%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	11.3%
Gelir büyüme oranı	8.1%
Özkaynak getirisi	17.0%
Net Marj	11.8%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Hanmi Pharm. Co., Ltd. (KRX:128940)

Nov 19

Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?

Nov 01

Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?

Oct 17

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate

Aug 16

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 24

Gelir ve Gider Dağılımı

Hanmi Pharm nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

KOSE:A128940 Gelir, gider ve kazançlar (KRW Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	1,568,781	184,377	422,608	185,996
31 Mar 24	1,533,383	158,086	425,449	181,612
31 Dec 23	1,490,887	146,231	422,595	181,769
30 Sep 23	1,419,708	131,316	417,941	172,935
30 Jun 23	1,397,244	101,982	417,863	173,702
31 Mar 23	1,371,607	106,424	415,433	164,490
31 Dec 22	1,331,547	82,792	410,340	154,317
30 Sep 22	1,330,854	80,780	406,247	145,044
30 Jun 22	1,291,788	78,807	390,821	141,929
31 Mar 22	1,253,997	67,497	377,286	145,622
31 Dec 21	1,203,186	67,025	361,309	146,027
30 Sep 21	1,130,015	77,337	343,349	140,632
30 Jun 21	1,093,865	23,092	334,837	184,352
31 Mar 21	1,057,969	23,462	319,870	192,925
31 Dec 20	1,075,854	11,959	319,555	212,387
30 Sep 20	1,101,450	-1,238	325,321	229,417
30 Jun 20	1,100,225	36,049	329,200	196,004
31 Mar 20	1,127,208	46,907	338,190	189,392
31 Dec 19	1,113,650	52,110	334,316	194,288
30 Sep 19	1,104,465	29,815	323,145	186,014
30 Jun 19	1,074,014	34,892	311,596	174,682
31 Mar 19	1,044,929	29,971	298,362	179,834
31 Dec 18	1,015,962	24,891	291,436	165,906
30 Sep 18	954,879	41,003	294,418	162,807
30 Jun 18	947,203	50,120	291,491	166,804
31 Mar 18	928,713	49,170	292,111	156,725
31 Dec 17	916,586	60,434	284,952	151,289
30 Sep 17	856,033	12,415	255,152	142,897
30 Jun 17	848,177	-3,433	260,920	139,067
31 Mar 17	859,901	4,177	277,865	142,438
31 Dec 16	882,725	23,326	291,189	142,894
30 Sep 16	1,300,579	220,192	440,412	153,498
30 Jun 16	1,349,235	188,682	457,339	155,392
31 Mar 16	1,359,164	179,858	459,716	162,805
31 Dec 15	1,317,535	154,443	450,085	167,987
30 Sep 15	939,070	9,750	319,290	167,011
30 Jun 15	850,027	37,587	287,695	163,529
31 Mar 15	791,905	33,760	256,965	151,272
31 Dec 14	761,280	35,510	244,990	135,168
30 Sep 14	743,779	32,302	242,562	119,832
30 Jun 14	750,634	45,249	247,498	110,621
31 Mar 14	743,951	45,870	253,115	101,862
31 Dec 13	730,134	43,933	251,671	94,965

Kaliteli Kazançlar: A128940 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: A128940 'nin mevcut net kar marjları (11.8%) geçen yılın (7.3%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: A128940 şirketinin kazançları son 5 yılda yılda 38.8% oranında önemli ölçüde arttı.

Büyüme Hızlandırma: A128940 'un son bir yıldaki kazanç büyümesi ( 80.8% ) 5 yıllık ortalamasını (yıllık 38.8% ) aşıyor.

Kazançlar vs. Sektör: A128940 geçen yılki kazanç büyümesi ( 80.8% ) Pharmaceuticals sektörünün 21.6% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: A128940 'nin Özsermaye Getirisi ( 17% ) düşük olarak değerlendiriliyor.

Hanmi Pharm Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Hanmi Pharm. Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Hanmi Pharm. Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024

Hanmi Pharm. Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Hanmi Pharm. Co., Ltd. to Report Q4, 2023 Results on Feb 02, 2024

Hanmi Pharm. Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Hanmi Pharm. Co., Ltd. (KRX:128940)

Investor sentiment deteriorates as stock falls 16%

Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?

Hanmi Pharm. Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate

Pinning Down Hanmi Pharm. Co., Ltd.'s (KRX:128940) P/E Is Difficult Right Now

Hanmi Pharm. Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024

Do Hanmi Pharm's (KRX:128940) Earnings Warrant Your Attention?

Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Consensus EPS estimates increase by 10%

Hanmi Pharm. Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Hanmi Pharm. Co., Ltd.'s (KRX:128940) Share Price Not Quite Adding Up

Now 21% undervalued after recent price drop

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Now 22% undervalued

New minor risk - Shareholder dilution

Hanmi Pharm. Co., Ltd. to Report Q4, 2023 Results on Feb 02, 2024

Upcoming dividend of ₩490 per share at 0.2% yield

Consensus EPS estimates increase by 10%

Hanmi Pharm. Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

Investor sentiment improves as stock rises 20%

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Consensus EPS estimates fall by 12%

Hanmi Pharm. Co., Ltd. to Report Q2, 2023 Results on Jul 28, 2023

First quarter 2023 earnings released: EPS: ₩3,467 (vs ₩1,566 in 1Q 2022)

Consensus EPS estimates increase by 24%

Investor sentiment improves as stock rises 19%

Full year 2022 earnings: EPS exceeds analyst expectations

Upcoming dividend of ₩490 per share

Less than half of directors are independent

Consensus EPS estimates increase by 13%

Now 25% undervalued after recent price drop

Consensus forecasts updated

Consensus EPS estimates increase by 28%

Less than half of directors are independent

Now 22% undervalued

Upcoming dividend of ₩490 per share

Hanmi Pharmaceutical Finds New Innovative Potential for Efpeglenatide

Price target increased to ₩385,044

Calculating The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Hanmi Pharm. Co., Ltd., Annual General Meeting, Mar 26, 2021

New 90-day low: ₩319,000

Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky

New 90-day high: ₩405,000

What Percentage Of Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Do Insiders Own?

New 90-day high: ₩394,000

Hanmi Pharm's (KRX:128940) Stock Price Has Reduced 48% In The Past Five Years

New 90-day high: ₩375,000

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate

New 90-day high: ₩327,500

Analysts lower EPS estimates to ₩2,279

Analysts update estimates

Price target raised to ₩342,471

New 90-day high - ₩284,500

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin